This is a working overview of fatty diacid, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-06. Anything still debated is marked as such rather than presented as settled.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 39-residue peptide | GIP-derived backbone with non-natural residues |
| Molar mass | Approximately 4.8 kDa | Peptide chain plus linker and lipid modifications |
| Appearance | White to off-white powder | Typical of lyophilized research material |
| Solubility | Soluble in water and aqueous buffer | Practically insoluble in nonpolar solvents |
| Storage temperature | Typically −20 °C for dry powder | Solutions usually held at 2–8 °C short term |
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
溶解操作一般使用注射用水或适宜的水性缓冲液，必要时加入少量助溶剂以改善溶解速度，但应避免剧烈涡旋振荡，因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态，具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分，则取决于用途是否为多次取样。
定量分析的主流方法是反相高效液相色谱联用紫外或质谱检测，利用肽在疏水固定相上的保留行为确定纯度与含量。对于生物基质中的浓度测定，常采用液相色谱串联质谱，并配合固相萃取或蛋白沉淀进行样品前处理。免疫分析法也可使用，但可能受到结构相关肽的交叉反应干扰。
纯度评估通常综合反相色谱、体积排阻色谱与质谱三方面信息：前者反映疏水性杂质，后者反映聚集体，质谱则确认分子量与主要降解产物。有关降解途径的完整图谱——例如脱酰胺、氧化与水解各占多大比例——在不同储存条件下仍有差异，属于需要逐案验证的问题。
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
=== Writing career === After writing several short stories, a novella and book reviews, his debut crime novel, Dead I Well May Be, was published by Scribner in 2003. The book was followed by two sequels in what would become to be known as the Michael Forsythe Trilogy. Alongside these, McKinty wrote the three books in his Lighthouse Trilogy, a series of science fiction young adult novels set in New York City, his native Ireland, and the fictional planet Altair. In 2008 McKinty moved with his family to Melbourne, Australia, to become a full-time writer. He found his greatest success and critical acclaim with the Sean Duffy series, following the eponymous Royal Ulster Constabulary Sergeant during The Troubles, beginning with 2012's The Cold Cold Ground. In 2019, the author made this comment about that novel: "It didn't sell very well, but it ended up getting the best reviews of my career. I got shortlisted for an Edgar, won a couple of awards, and so then that set me on that path for the next six years of reluctantly, kind of being dragged into writing about Northern Ireland in the 1980s". The third Duffy book, In the Morning I'll Be Gone, won the 2014 Ned Kelly Award for Best Novel. McKinty has been an especially astute observer of class in fiction. He also began working as a writer and reviewer for a number of publications including The Guardian, The Sydney Morning Herald, The Washington Post, The Independent, The Australian, The Irish Times and Harpers.
To carry out its work, the search unit would collect the necessary information about missing persons, analyze the information collected, strengthen and streamline processes for identifying mortal remains in coordination with the National Institute of Legal Medicine and Forensic Sciences, guarantee families' participation, and present an official report to families informing them of the fate of missing relatives. The search unit would be administrative and financially independent and autonomous, complementing the other components of the Comprehensive System.
Desirable: <14 mg/dL (<35 nmol/L) Borderline risk: 14–30 mg/dL (35–75 nmol/L) High risk: 31–50 mg/dL (75–125 nmol/L) Very high risk: >50 mg/dL (>125 nmol/L) Lp(a) appears with different isoforms (per kringle repeats) of apolipoprotein; 40% of the variation in Lp(a) levels when measured in mg/dl can be attributed to different isoforms. Lighter Lp(a) are also associated with disease. Thus, a test with simple quantitative results may not provide a complete assessment of risk. The US FDA has given the Tina-quant® lipoprotein Lp(a) RxDx assay from Roche a Breakthrough Device Designation. The assay is designed to identify patients who may benefit from therapies aimed at decreasing Lp(a) levels.
== Symptoms == Soon after its discovery, scientists injected phalloidin into mice and discovered its LD50 is 2 mg/kg via IP injection. When exposed to the minimum lethal dose, it took several days for these mice to die. The only apparent side effect of phalloidin poisoning is extreme hunger. This is because phalloidin is only taken up by the liver via bile salt membrane transport proteins. Once inside the liver, phalloidin binds F-actin, preventing its depolymerization. It takes time for this process to destroy the liver cells. The kidneys can also take up phalloidin, but not as effectively as the liver. Here, phalloidin causes nephrosis.
Sources: en.wikipedia.org
The climate of Brazil comprises a wide range of weather conditions across a large area and varied topography, but most of the country is tropical. According to the Köppen system, Brazil hosts six major climatic subtypes: desert, equatorial, tropical, semiarid, oceanic and subtropical. The different climatic conditions produce environments ranging from equatorial rainforests in the north and semiarid deserts in the northeast, to temperate coniferous forests in the south and tropical savannas in central Brazil. In Brazil, forest cover is around 59% of the total land area, equivalent to 496,619,600 hectares (ha) of forest in 2020, down from 588,898,000 hectares (ha) in 1990. In 2020, naturally regenerating forest covered 485,396,000 hectares (ha) and planted forest covered 11,223,600 hectares (ha). Of the naturally regenerating forest, 44% was reported to be primary forest (consisting of native tree species with no clearly visible indications of human activity) and around 30% of the forest area was found within protected areas. For 2015, 56% of the forest area was reported to be under public ownership and 44% private ownership. Many regions have starkly different microclimates. An equatorial climate characterizes much of northern Brazil. There is no real dry season, but there are some variations in the period of the year when most rain falls. Temperatures average 25 °C (77 °F), with more significant temperature variation between night and day than between seasons. Over central Brazil, rainfall is more seasonal, characteristic of a savanna climate.
Body mass index (BMI) is acceptable for determining obesity for children two years of age and older. It is determined by the ratio of weight to height. The normal range for BMI in children vary with age and sex. While a BMI above the 85th percentile is defined as overweight, a BMI greater than or equal to the 95th percentile is defined as obesity by the Centers for Disease Control and Prevention (CDC). Obesity is further categorized as class 1 obesity with BMI at or above the 95th percentile to 119% of the 95th percentile, class 2 obesity with a BMI 120 to 139% of the 95% percentile and class 3 obesity which is 140% or greater of the 95th percentile. The CDC has published tables for determining this in children. The US Preventive Service Task Force reported that not all children with a high BMI need to lose weight, however. High BMI can identify a possible weight problem, but does not differentiate between fat or lean tissue. Additionally, BMI may mistakenly rule out some children who do have excess adipose tissue. It is therefore beneficial to supplement the reliability of a BMI diagnosis with additional screening tools such as adipose tissue or skin fold measurements.
== Process == Chemical gardens rely on most transition-metal silicates being insoluble in water and colored. When a metal salt, such as cobalt chloride, is added to a sodium silicate solution, it will start to dissolve. It will then form insoluble cobalt silicate by a double displacement reaction. This cobalt silicate is a semipermeable membrane. Because the ionic strength of the cobalt solution inside the membrane is higher than that of the sodium silicate solution, which forms the bulk of the tank contents, osmotic effects will increase the pressure within the membrane. This will cause the membrane to rupture, forming a hole. The cobalt cations will react with the silicate anions at this opening to form a new solid. In this way, growths will form in the tanks; they will be colored (according to the metal cation) and may look like plant-like structures. The growth of chemical gardens is governed by the combined effect of osmotic pressure and buoyancy-driven convection. Osmotic pressure across the semipermeable membrane increases the internal pressure until the membrane ruptures, while buoyancy driven flow promotes the upward growth of the tubular structures. The usual upward growth direction depends on the density of the fluid inside the semipermeable membrane of the "plant" being lower than that of the surrounding waterglass solution. If a metal salt produces a very dense fluid inside the membrane, growth is downward.
Sources: en.wikipedia.org
The investigators found that SAGE systems were nontoxic in vivo, and were capable of eliciting CD4 T cell and B cell responses in the case of the tetanus toxoid and ovalbumin systems while eliciting a CD8 T cell response with the hemagglutinin system. Some advantages to using SAGE systems for antigen presentation include the ability to remain stable and functional after functionalization with cargo, the ability to modify and tune cellular uptake properties, and the modularity of the platform which could potentially be used to present multiple antigens at the same time, resulting in increased antigen immunogenicity. Another type of coiled-coil nanoparticle system is the self-assembling protein nanoparticles (SAPN). SAPN differs from SAGE in that SAPN utilizes trimeric and pentameric coiled-coil motifs. This change results in the self-assembly of a symmetrical polyhedral 16 nm nanoparticle composed of 60 monomer building blocks. The small size of SAPN allows the nanoparticle system to resemble viruses in shape and size, which is beneficial to antigen presentation. Specifically, SAPN has been utilized by Dr. David Lanar and colleagues to develop a P. falciparum malaria vaccine whereby B and CD8-T cell epitopes of the disease were modified into the SAPN coiled-coil motifs. In vivo results showed that a long-lasting immune response was generated in the mice for up to 13 months, capable of preventing malaria infection in vaccine-treated mice.
DART can be used for the analysis of solid, liquid or gaseous samples. Liquids are typically analyzed by dipping an object (such as a glass rod) into the liquid sample and then presenting it to the DART ion source. Vapors are introduced directly into the DART gas stream.
Room temperature, colloquially, denotes the range of air temperatures most people find comfortable indoors while dressed in typical clothing. Comfortable temperatures can be extended beyond this range depending on humidity, air circulation, among other factors. In certain fields, like science and engineering, and within a particular context, room temperature can mean different agreed-upon ranges. In contrast, ambient temperature is the actual temperature, as measured by a thermometer, of the air (or other medium and surroundings) in any particular place. The ambient temperature (e.g. an unheated room in winter) may be very different from an ideal room temperature. Food and beverages may be served at "room temperature", meaning neither heated nor cooled.
==== Air tray drying ==== Tempeh can be dried via the air tray drying method. Cubes of tempeh placed on steel, mesh bottom trays are dried by the circulating hot air dryer. After the product is finished, they can be cut into 2.5-centimetre (1-inch) squares at 90 °C (200 °F) for 90 to 120 minutes in order to reduce moisture content to 2–4%. When placed in moisture proof Pliofilm bags, the tempeh has a shelf life of several months at room temperature. Although this is a convenient method that produces a shelf stable product without requirement of refrigeration, the process of hot air drying can cause a significant loss of nutritional content such as the soluble solids and nitrogen protein content.
Sources: en.wikipedia.org
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.
It is given by subcutaneous injection, generally on a weekly schedule. Dosing usually begins low and increases in steps to limit gastrointestinal side effects. Formulated product is supplied as a ready-to-use pen or vial in most markets.
No. Receptor engagement is documented, but how central appetite circuits, gut signals, and insulinotropic effects combine is incompletely resolved. Investigators continue to separate GIP-driven from GLP-1-driven contributions in animal and human models.
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.